Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2017 07:00 ET | Source: Cempra, Inc.

Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI

—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
December 12, 2016 09:01 ET | Source: Cempra, Inc.

Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President

—Leadership changes bolster manufacturing, regulatory and commercial expertise— —Cempra founder, president and CEO, Dr. Prabhavathi Fernandes, announces retirement from the company and...
June 28, 2016 07:00 ET | Source: Cempra, Inc.

Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia

CHAPEL HILL, N.C., June 28, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
September 18, 2015 07:00 ET | Source: Melinta Therapeutics, Inc.

FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic

CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
April 17, 2015 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present at Two Upcoming Scientific Conferences

CHAPEL HILL, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...